PYY3-36: The Satiety Hormone and Its Therapeutic Promise
Peptide YY3-36 (PYY3-36) is a gut hormone that plays a crucial role in regulating appetite and food intake. Secreted by the L-cells of the small intestine and colon in response to feeding, PYY3-36 acts as a natural satiety signal, informing the brain that the body is full. This has made it a subject of intense research for its potential as a therapeutic agent for obesity and related metabolic conditions.
Mechanism of Action: How PYY3-36 Curbs Appetite
The primary mechanism by which PYY3-36 reduces food intake is through its interaction with the Y2 receptor in the hypothalamus, a key region of the brain responsible for controlling hunger and satiety. By binding to the Y2 receptor, PYY3-36 inhibits the release of neuropeptide Y (NPY), a potent appetite stimulant. This action leads to a decrease in hunger and an increase in the feeling of fullness, ultimately resulting in reduced calorie consumption. The potent anorectic effects of PYY3-36 have been demonstrated in numerous preclinical and clinical studies [1].
Clinical Data on PYY3-36 for Weight Management
Several clinical trials have investigated the efficacy and safety of PYY3-36 for weight reduction in obese adults. An early proof-of-concept study involving intranasal administration of PYY3-36 showed a trend towards weight loss, although it was not statistically significant [2]. More recent research has focused on developing long-acting analogs of PYY3-36 to enhance its therapeutic potential. A phase 2 clinical trial of a long-acting PYY3-36 analogue, PYY1875, demonstrated significant weight loss when used as an add-on therapy to semaglutide, a GLP-1 receptor agonist [3]. This suggests that combination therapies involving PYY3-36 may be a particularly effective strategy for obesity treatment.
| Study | Intervention | Key Findings |
|---|---|---|
| Gantz et al. (2007) [2] | Intranasal PYY3-36 | Trend towards weight loss, not statistically significant. |
| Wulff et al. (2025) [3] | PYY1875 (long-acting PYY3-36 analog) + Semaglutide | Significant weight loss compared to semaglutide alone. |
| ClinicalTrials.gov NCT00537420 | Nasal PYY3-36 | Completed Phase 2 trial for weight loss in obese subjects. |
Practical Applications and Future Directions
The practical application of PYY3-36 in a clinical setting is still under investigation. The development of long-acting formulations and combination therapies is a key area of focus. The additive or synergistic effects observed when PYY3-36 is combined with other gut hormones like GLP-1 suggest that multi-agonist drugs could be the future of obesity treatment. Furthermore, research is ongoing to explore different delivery methods, such as oral formulations, to improve patient convenience and adherence. The self-assembling behavior of PYY3-36 is also being studied for its potential in developing novel drug delivery systems.
Safety and Tolerability
In clinical trials, PYY3-36 has been generally well-tolerated. The most commonly reported side effects are mild and transient, including nausea and headache. The safety profile of long-acting PYY3-36 analogs, both alone and in combination with other medications, is a critical aspect of ongoing research.
Key Takeaways
- PYY3-36 is a gut hormone that acts as a natural satiety signal.
- It reduces appetite by inhibiting the release of neuropeptide Y (NPY) in the hypothalamus.
- Clinical trials have shown its potential for weight loss, particularly in combination with other gut hormone-based therapies.
- The development of long-acting analogs and novel delivery systems is a key area of ongoing research.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any peptide therapy or making changes to your health regimen.
References
[1] Karra, E., & Batterham, R. L. (2009). The role of peptide YY in appetite regulation and obesity. Journal of physiology, 587(1), 19-25. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670018/ [2] Gantz, I., Erondu, N., Mallick, M., Musser, B., & Stribling, R. (2007). Efficacy and safety of intranasal peptide YY3–36 for weight reduction in obese adults. The Journal of Clinical Endocrinology & Metabolism, 92(5), 1754-1757. https://academic.oup.com/jcem/article/92/5/1754/2598496 [3] Wulff, B. S., Chambers, A. P., Osorto Contreras, C. K., et al. (2025). Long‐acting PYY3−36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies. Obesity. https://onlinelibrary.wiley.com/doi/abs/10.1002/oby.24329
